SILDENAFIL CITRATE - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for sildenafil citrate and what is the scope of freedom to operate?

Sildenafil citrate is the generic ingredient in four branded drugs marketed by Viatris, Ajanta Pharma Ltd, Alkem Labs Ltd, Amneal Pharms, Appco, Aptapharma Inc, Aurobindo Pharma Ltd, Granules, Hetero Labs Ltd V, Lupin Ltd, MSN, Novitium Pharma, Taro, Teva Pharms Usa, Tris Pharma Inc, Zydus Lifesciences, Eugia Pharma, Cmp Dev Llc, Actavis Grp Ptc, Amneal Pharms Ny, Apotex Corp, Cadila Pharms Ltd, Chartwell Rx, Macleods Pharms Ltd, Mylan, Mylan Pharms Inc, Perrigo R And D, Reyoung, Rubicon, Sunshine, Teva, Teva Pharms, Torrent, Torrent Pharms Ltd, Umedica, and Watson Labs Inc, and is included in fifty-two NDAs. There are four patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Sildenafil citrate has nine patent family members in nine countries.

There are eighteen drug master file entries for sildenafil citrate. Sixty-eight suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for SILDENAFIL CITRATE

International Patents:	9
US Patents:	4
Tradenames:	4
Applicants:	36
NDAs:	52
Drug Master File Entries:	18
Finished Product Suppliers / Packagers:	68
Raw Ingredient (Bulk) Api Vendors:	114
Clinical Trials:	138
Patent Applications:	7,181
Drug Prices:	Drug price trends for SILDENAFIL CITRATE
Drug Sales Revenues:	Drug sales revenues for SILDENAFIL CITRATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SILDENAFIL CITRATE
What excipients (inactive ingredients) are in SILDENAFIL CITRATE?	SILDENAFIL CITRATE excipients list
DailyMed Link:	SILDENAFIL CITRATE at DailyMed

See drug prices for SILDENAFIL CITRATE

Drug Sales Revenue Trends for SILDENAFIL CITRATE

See drug sales revenues for SILDENAFIL CITRATE

Recent Clinical Trials for SILDENAFIL CITRATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Batterjee Medical College	Phase 4
University of Pennsylvania	Phase 2
Ladoke Akintola University of Technology Teaching Hospital, Ogbomoso	Phase 4

See all SILDENAFIL CITRATE clinical trials

Generic filers with tentative approvals for SILDENAFIL CITRATE

Applicant	Application No.	Strength	Dosage Form
⤷ Sign Up	⤷ Sign Up	100MG	TABLET; ORAL
⤷ Sign Up	⤷ Sign Up	50MG	TABLET; ORAL
⤷ Sign Up	⤷ Sign Up	25MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for SILDENAFIL CITRATE

Drug Class	Phosphodiesterase 5 Inhibitor
Mechanism of Action	Phosphodiesterase 5 Inhibitors

Medical Subject Heading (MeSH) Categories for SILDENAFIL CITRATE

Phosphodiesterase 5 Inhibitors
Urological Agents
Vasodilator Agents

Anatomical Therapeutic Chemical (ATC) Classes for SILDENAFIL CITRATE

G04BE	Drugs used in erectile dysfunction
G04B	UROLOGICALS
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for SILDENAFIL CITRATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIAGRA	Tablets	sildenafil citrate	25 mg and 50 mg	020895	1	2004-11-19
VIAGRA	Tablets	sildenafil citrate	100 mg	020895	1	2004-10-25

US Patents and Regulatory Information for SILDENAFIL CITRATE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	SILDENAFIL CITRATE	sildenafil citrate	TABLET;ORAL	077342-003	Mar 9, 2016	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Teva Pharms Usa	SILDENAFIL CITRATE	sildenafil citrate	FOR SUSPENSION;ORAL	211534-001	May 29, 2020	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Zydus Lifesciences	SILDENAFIL CITRATE	sildenafil citrate	FOR SUSPENSION;ORAL	215708-001	Sep 29, 2022	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Amneal Pharms Ny	SILDENAFIL CITRATE	sildenafil citrate	TABLET;ORAL	202023-003	Jun 27, 2018	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Appco	SILDENAFIL CITRATE	sildenafil citrate	TABLET;ORAL	207178-003	Mar 2, 2020	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Viatris	REVATIO	sildenafil citrate	TABLET;ORAL	021845-001	Jun 3, 2005	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Aurobindo Pharma Ltd	SILDENAFIL CITRATE	sildenafil citrate	TABLET;ORAL	203962-002	Jun 11, 2018	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for SILDENAFIL CITRATE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-001	Mar 27, 1998	⤷ Sign Up	⤷ Sign Up
Viatris	REVATIO	sildenafil citrate	SOLUTION;INTRAVENOUS	022473-001	Nov 18, 2009	⤷ Sign Up	⤷ Sign Up
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-003	Mar 27, 1998	⤷ Sign Up	⤷ Sign Up
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-003	Mar 27, 1998	⤷ Sign Up	⤷ Sign Up
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-002	Mar 27, 1998	⤷ Sign Up	⤷ Sign Up
Viatris	REVATIO	sildenafil citrate	TABLET;ORAL	021845-001	Jun 3, 2005	⤷ Sign Up	⤷ Sign Up
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-002	Mar 27, 1998	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for SILDENAFIL CITRATE

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2019130052		⤷ Sign Up
Singapore	11202006080S	LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS	⤷ Sign Up
Brazil	112020012986	formulações orais líquidas para inibidores de pde v	⤷ Sign Up
Japan	2021509114	ＰＤＥＶ阻害剤のための液体経口処方物	⤷ Sign Up
Morocco	50320	Formulations orales liquides pour inhibiteurs de pde v	⤷ Sign Up
Canada	3086881	FORMULATIONS ORALES LIQUIDES POUR INHIBITEURS DE PDE V (LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS)	⤷ Sign Up
Australia	2018397436	Liquid oral formulations for PDE V inhibitors	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for SILDENAFIL CITRATE

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0463756	99C0007	Belgium	⤷ Sign Up	PRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756	C990005	Netherlands	⤷ Sign Up	PRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756	SPC/GB99/004	United Kingdom	⤷ Sign Up	PRODUCT NAME: SILDENAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE CITRATE SALT; REGISTERED: CH 54642 19980622; UK EU/1/98/077/001 19980914; UK EU/1/98/077/002 19980914; UK EU/1/98/077/003 19980914; UK EU/1/98/077/004 19980914; UK EU/1/98/077/005 19980914; UK EU/1/98/077/006 19980914; UK EU/1/98/077/007 19980914; UK EU/1/98/077/008 19980914; UK EU/1/98/077/009 19980914; UK EU/1/98/077/010 19980914; UK EU/1/98/077/011 19980914; UK EU/1/98/077/012 19980914
0463756	5/1999	Austria	⤷ Sign Up	PRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.